Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
KANTARJIAN, HAGOP M
One or more keywords matched the following items that are connected to KANTARJIAN, HAGOP M
Item TypeName
Academic Article Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.
Academic Article Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Academic Article RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.
Academic Article Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.
Academic Article DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.
Academic Article DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Academic Article Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
Academic Article Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
Concept DNA Methylation
Concept Methylation
Academic Article Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.
Academic Article TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Academic Article Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia.
Academic Article Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Academic Article The role of decitabine in the treatment of myelodysplastic syndromes.
Academic Article Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
Academic Article Low frequency of H3.3 mutations and upregulated DAXX expression in MDS.
Academic Article Myeloproliferative disorders: usefulness of X-linked probes in diagnosis.
Academic Article Loss of imprinting in disease progression in chronic myelogenous leukemia.
Academic Article Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes.
Academic Article DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia.
Academic Article Azacitidine.
Academic Article Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article Decitabine and its role in the treatment of hematopoietic malignancies.
Academic Article Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
Academic Article Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
Academic Article Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Academic Article Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Academic Article Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.
Academic Article Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
Academic Article Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Academic Article Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".
Academic Article DNA methylation in haematological malignancies: the role of decitabine.
Academic Article Investigational strategies in chronic myelogenous leukemia.
Academic Article Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status.
Academic Article Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.
Academic Article Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Academic Article Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Academic Article Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Academic Article Targeting DNA methylation.
Academic Article Current and future management options for myelodysplastic syndromes.
Academic Article Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Academic Article Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
Academic Article Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Academic Article Azacitidine.
Academic Article Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia.
Academic Article A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Academic Article Epigenetics of acute lymphocytic leukemia.
Academic Article Decitabine in the treatment of myelodysplastic syndromes.
Academic Article Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Academic Article Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia.
Academic Article Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Academic Article Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
Academic Article RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
Academic Article Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Academic Article TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
Academic Article Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.
Academic Article Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.
Academic Article MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
Academic Article MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
Academic Article Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML
Academic Article Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
Academic Article Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Academic Article Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Academic Article A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome.
Academic Article Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
Academic Article Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Academic Article Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.
Academic Article Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Academic Article The emerging role of immune checkpoint based approaches in AML and MDS.
Academic Article Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
Academic Article Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
Academic Article Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Academic Article Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
Academic Article Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.
Academic Article Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Academic Article Germline DNMT3A mutation in familial acute myeloid leukaemia.
Academic Article Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.
Academic Article Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Academic Article Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Academic Article Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Search Criteria
  • Methylation